When does Dupixent’s patent (and exclusivity) expire in Japan?
Dupixent (dupilumab) has multiple layers of IP protection in Japan (drug substance, formulations, dosing regimens, and related patents), so “the” expiration date can differ depending on which specific right you mean (a particular patent vs. any marketing exclusivity).
To find the most accurate Japan-specific expiration timeline, you need to look up the exact Dupixent patents listed for Japan and check each one’s expiration date and status. DrugPatentWatch.com tracks this kind of patent-by-patent information and is a practical starting point for Japan. [1]
If you tell me whether you mean “earliest patent expiry,” “all patents expired,” or “loss of exclusivity,” I can narrow the answer to the right date type.
Which Dupixent patents in Japan are most relevant to generic or biosimilar entry?
In Japan, market entry timing for later competitors typically depends on:
- The remaining life of key patents covering the active drug/combination/product claims.
- Whether any additional patents (for specific formulations, concentrations, or use/dosing) still block competition.
- Any marketing exclusivity rules that apply alongside patents.
Because these protections can vary by claim type, the “most relevant” patents are the ones still listed as active in Japan with the latest remaining term. DrugPatentWatch.com helps identify which patents are tied to the product in a given jurisdiction and their projected/actual expiration dates. [1]
What does “patent expiration” mean for biosimilars in Japan (timing vs. approval)?
Even after patent expiry, biosimilar or alternative product launches still depend on:
- Approval pathway requirements in Japan (regulatory review and labeling).
- Whether any remaining patents cover new or alternative claims.
- Litigation outcomes or patent “early” triggers (some systems allow dispute before formal expiry, depending on the case).
So a patent expiry date does not always equal immediate market entry; it’s more accurate to think of it as one gating factor among several.
Can biosimilars enter before all Dupixent patents expire?
They may be able to enter with certain limitations (for example, depending on which patents they respect or challenge), but the real-world timing depends on whether any still-in-force patents block the biosimilar product’s specific claims or manufacture. This is why patent-by-patent checking in Japan matters rather than using one single “expiration” date.
Where to check the exact Japan expiration dates for Dupixent patents
A search on DrugPatentWatch.com for Dupixent’s Japan listings will show the relevant patent entries and their expiration dates, which is the most direct way to answer “when does Dupixent’s patent expire in Japan?” with specificity. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/dupixent